Fri.Feb 07, 2025

article thumbnail

STAT+: Class action suit over UnitedHealth’s AI care denials nears key moment

STAT

A federal judge will soon decide whether a class action lawsuit against UnitedHealth Group and its algorithm-based care denials can move forward, which would potentially open the door for attorneys to sift through the company’s internal communications. The lawsuit, in U.S. District Court in Minnesota, alleges that UnitedHealth and its subsidiary NaviHealth relied on flawed algorithms to cut off essential rehabilitative care to sick and injured Medicare Advantage beneficiaries.

article thumbnail

Seven million hours of pharmacy access lost in two years

The Pharmacist

Patients in England have lost around seven million hours of pharmacy access in the last two years, analysis from the National Pharmacy Association (NPA) has suggested. And around one in eight have seen their local pharmacy close for good, the NPA said. Inadequate funding could force pharmacies to reduce access by a further one million […] The post Seven million hours of pharmacy access lost in two years appeared first on The Pharmacist.

102
102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Lawmakers ask FDA to review Hims’ Super Bowl ad for ‘misleading’ patients

STAT

Ahead of the Super Bowl, telehealth company Hims & Hers on Jan. 28 released a provocative commercia l attacking the weight loss industry to get attention. And it’s done just that: Lawmakers now want the Food and Drug Administration to review whether the ad runs afoul of pharmaceutical advertising rules.  In a letter sent Friday morning to FDA acting Commissioner Sara Brenner, Sens.

article thumbnail

Pharma M&A and venture capital deals reach $33.7 billion in Jan 2025

Express Pharma

The healthcare industry reported 107 mergers and acquisitions (M&A) deals worth $29.2 billion in January 2025, according to data from GlobalData. This is higher than the last 12-month (January 2024 to December 2024) average of 99 deals worth $14 billion. Johnson & Johnson announced the acquisition of Intra-Cellular Therapies, a biopharmaceutical company, for a total equity value of approximately $14.6 billion.

article thumbnail

Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

article thumbnail

Opinion: STAT+: We need a universal approach to sharing biomedical samples   

STAT

Three years ago, I was working at a biotech company leading a drug discovery program focused on metabolic disease. Interested in obtaining liver samples that could help identify potential therapeutic targets, I learned that a tenured professor at a top 10 NIH institution had more than 2,000 samples of tissue from patients they had accumulated over more than a decade of research.

Bioethics 184

More Trending

article thumbnail

Q&A: New York’s plan for boosting life expectancy, neighborhood by neighborhood

STAT

All health is local, down to neighborhoods that shave years off life expectancy, public health officials in New York City assert in a new, data-driven strategy intended to reverse the trend toward shorter lifespans that accelerated during the pandemic. “Health is as much about your neighborhood and your environment as it is about an individual checkup or prescription,” acting health commissioner Michelle Morse wrote in introducing a roadmap to better health.

Diabetes 153
article thumbnail

Tariffs raise concern among generic drugmakers, and advocacy groups are seeking exemptions

PharmaVoice

While the 10% tariff on Chinese goods won’t have too much impact on branded drugs, generics are struggling to pivot.

173
173
article thumbnail

STAT+: Up and down the ladder: The latest comings and goings

STAT

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

143
143
article thumbnail

India Ratings and Research maintains Neutral Outlook for pharmaceuticals sector in FY26

Express Pharma

India Ratings and Research (Ind-Ra) has maintained a Neutral Outlook for the pharmaceuticals sector in FY26. The agency projects overall revenue growth of 9 per cent-10 per cent year-on-year, driven by growth in the domestic chronic segment, US generics, and the contract development and manufacturing organisation (CDMO) business. EBITDA margins are expected to remain at historically elevated levels over FY25-FY26, supported by growth in high-value products, moderation in pricing pressures, cost

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Signs of life at the CDC

STAT

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.  Sign up here. Good morning.

217
217
article thumbnail

Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner

Drug Channels

Todays guest post comes from Richard Faris, Chief Strategy & Growth Officer at PANTHERx Rare Pharmacy. Richard outlines the key factors for commercialization success when a manufacturer launches treatments for rare and orphan diseases. He explains the key considerations for choosing a specialty pharmacy network design, selecting the right pharmacy partners, and establishing patient services HUBs.

article thumbnail

Biologic could reduce treatment burden for children with haemophilia A

European Pharmaceutical Review

Interim results from a Phase III trial have demonstrated promising efficiency of Novo Nordisks Factor VIIIa (FVIIIa) mimetic bispecific antibody in children living with haemophilia A with and without inhibitors.The FRONTIER3 trial evaluating Mim8 enrolled a total of 70 children aged between one and 11 years old. Key outcomes from the FRONTIER3 trial Part one of the study involved participants receiving once-weekly doses of the treatment.

article thumbnail

Bristol Myers gives first peek at closely watched launch of schizophrenia drug

PharmaVoice

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.

130
130
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn

Pharmaceutical Technology

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the strong growth potential of Japans healthcare industry.

104
104
article thumbnail

FDA starts review of first bronchiectasis drug candidate

pharmaphorum

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for bronchiectasis in the US.

93
article thumbnail

Sanofi increases ownership stake partaking in pharma buyback trend

Pharmaceutical Technology

Sanofi has agreed to purchase its own shares worth 2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

98
article thumbnail

Tariffs raise concern among generic drugmakers, as advocacy groups seek exemptions

BioPharma Dive

“There is not a single member of AAM who has not raised concerns about the tariff situation,” said the CEO of the generic drug lobby Association for Accessible Medicines.

91
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Treating alcohol addiction: filling the medication gap

Pharmaceutical Technology

With Dry January firmly behind us, many adults are prompted to reassess their relationship with alcohol. Alcohol Change, the UK charity behind the popular Dry January initiative, found that 30% of men and 26% of women in the UK wished to reduce the amount of alcohol they drank in 2024.

85
article thumbnail

Bain buys Japanese pharma Mitsubishi Tanabe for $3.4bn

pharmaphorum

Bain Capital has agreed to buy Mitsubishi Tanabe for around $3.

71
article thumbnail

EMCrit 394 – CV-EMCrit – Inotrope Basics Part 2 – Specific Scenarios

EMCrit Project

Part 2 of Inotropes with Trina - we discuss specific scenarios. EMCrit Project by Scott Weingart, MD FCCM.

67
article thumbnail

Immune drugmakers Alumis and Acelyrin to merge

BioPharma Dive

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the new company with a bigger cash balance and three drugs in testing.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Industry Outlook 2025: The Rising Prominence of AI in Pharma

PharmaTech

In this interview, Pharmaceutical Technology discusses the trend of AI in pharma and how it may play out in 2025 and beyond with Ben Sidders from Biorelate.

64
article thumbnail

Relmada acquires Tourette’s therapy rights from Asarina

Pharmaceutical Technology

Relmada has acquired complete ownership rights to Sepranolone, developed for Tourette syndrome (TS) from Asarina Pharma.

64
article thumbnail

Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty

BioPharma Dive

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff.

62
article thumbnail

Video: GLP-1 Medications Revolutionize Obesity and Diabetes Care, With Exciting Advances on Horizon

Pharmacy Times

Donna Ryan discusses the landscape of GLP-1 medications and the lineup of indications that the drug class has received indications for in recent years.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Recipharm Launches New Fully Operational Modular Sterile Filling System in Germany

PharmaTech

Installation was performed during the summer of 2024, and the system has already successfully completed its first production run for a leading biotech company.

59
article thumbnail

M&A in Pharma: Balancing Growth and Risk

Pharmaceutical Commerce

What factors should be consideredand how can both parties benefit long-term?

59
article thumbnail

AdvanCell Completes $112 Million Oversubscribed Series C Financing

PharmaTech

Patient enrollment is currently underway for the highest-dose cohort of AdvanCells potentially best-in-class targeted alpha therapy for metastatic prostate cancer.

59